Drugs / 18F-FAPI
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05691894 | Nov 2022 → Nov 2023 | cancer | Affiliated Hospital of Jiangnan University | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05749302 | Jan 2023 → Mar 2025 | cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT05810324 | Jul 2022 → Jul 2024 | cancer | Jilin University | Unknown | No outcome recorded |
| — | NCT05884463 | Apr 2021 → Feb 2023 | pancreatic adenocarcinoma | Zhejiang University | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18F-FAPI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05810324 ↗ |
| Known as | Al18F-NOTA-FAPI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05749302 ↗ |
| Modality | Diagnostic / imaging agent | “tracer targeting FAP PET Imaging” NCT05691894 ↗ |
| Route | Intravenous | “single intravenous injection of 18F-FAPI” NCT05810324 ↗ |
| Target | FAP | “tracer targeting FAP PET Imaging” NCT05691894 ↗ |